Recombinant VP1 protein of norovirus GII.4 (Caliciviridae: <i>Norovirus</i>) is capable to induse the production of cross-reacting antibodies
Introduction. Norovirus (NoV) is one of the main causes of acute gastroenteritis. Currently, there is no vaccine to prevent norovirus infection. Vaccines under development are based on the capsid protein VP1, which is capable of forming virus-like particles. The aim of the work was to analyze the...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Central Research Institute for Epidemiology
2025-07-01
|
| Series: | Вопросы вирусологии |
| Subjects: | |
| Online Access: | https://virusjour.crie.ru/jour/article/viewFile/16753/989 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. Norovirus (NoV) is one of the main causes of acute gastroenteritis. Currently, there is no vaccine to prevent norovirus infection. Vaccines under development are based on the capsid protein VP1, which is capable of forming virus-like particles.
The aim of the work was to analyze the immunogenic properties of the recombinant VP1 protein of NoV GII.4.
Materials and methods. In the blood serum of animals immunized with the recombinant VP1 protein obtained by the authors, titers and avidity of total antibodies and IgM antibodies against NoV VP1 were determined using enzyme immunoassay. The ability of the obtained antibodies to interact with NoV of different genotypes was assessed using immunoelectron microscopy.
Results. The recombinant VP1 protein induced high titer antibody production in animals. Total antibodies against VP1 had a high avidity, reaching 100%, which suggests that they have viral neutralizing activity. IgM antibodies had low avidity. Immunoelectron microscopy showed that IgG antibodies against VP1 protein of genotype GII.4 interact with wild-type NoV of genotype GII.7 and GII.17.
Conclusion. The obtained recombinant protein induces a sufficiently strong immune response with the formation of high avidity polyclonal cross-reacting antibodies, which allows us to consider it as an antigen component of a NoV vaccine candidate. |
|---|---|
| ISSN: | 0507-4088 2411-2097 |